Piper Jaffray analyst Christopher Raymond keeps a Neutral rating and $305 price target on Biogen shares, noting that, according to Wolters Kluwer Health, Biogen took meaningful price increases on most of its key MS franchise drugs, effective January 1. Raymond tells investors in a research note that he thinks these increases are consistent with established patterns in terms of timing and magnitude, which he also thinks is notable given the level of scrutiny on drug pricing on the policy and political front. The analyst says he continues to see "business as usual on this front," despite years of intense political attention, and says Biogen is not the only player to continue this practice of regular meaningful price increases.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here